The Place of Insulin Secretagogues in the Treatment of Type 2 Diabetes in the Twenty-First Century

  • Harald Stingl
  • Guntram Schernthaner

Keywords: Sulfonylurea, glinides, insulin secretagogue, hypoglycaemia, cardiovascular, insulin resistance.


Insulin Secretion Beta Cell Fast Plasma Glucose Insulin Secretagogue Sulfonylurea Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37(12): 1595–1607.CrossRefPubMedGoogle Scholar
  2. 2.
    Polonsky KS. Lilly lecture 1994. The beta-cell in diabetes: from molecular genetics to clinical research. Diabetes 1995;44(6):705–717.CrossRefPubMedGoogle Scholar
  3. 3.
    Weyer C, Tataranni PA, Bogardus C, Pratley RE. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care 2001;24(1):89–94.CrossRefPubMedGoogle Scholar
  4. 4.
    DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999;131(4):281–303.PubMedGoogle Scholar
  5. 5.
    DeFronzo RA. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988;37(6):667–687.PubMedGoogle Scholar
  6. 6.
    UKPDS. UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. UK Prospective Diabetes Study Group. Diabetes 1995;44(11):1249–1258.CrossRefGoogle Scholar
  7. 7.
    Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999;104(6):787–794.CrossRefPubMedGoogle Scholar
  8. 8.
    Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA. Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia 2004;47(1): 31–39.CrossRefPubMedGoogle Scholar
  9. 9.
    Del Prato S, Pulizzi N. The place of sulfonylureas in the therapy for type 2 diabetes mellitus. Metabolism 2006;55(5 Suppl 1):S20–S27.PubMedGoogle Scholar
  10. 10.
    Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002;287(3): 360–372.CrossRefPubMedGoogle Scholar
  11. 11.
    UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352(9131):837–853.CrossRefGoogle Scholar
  12. 12.
    UKPDS. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352(9131):854–865.CrossRefGoogle Scholar
  13. 13.
    Groop L, Luzi L, Melander A, Groop PH, Ratheiser K, Simonson DC, DeFronzo RA. Different effects of glyburide and glipizide on insulin secretion and hepatic glucose production in normal and NIDDM subjects. Diabetes 1987;36(11):1320–1328.CrossRefPubMedGoogle Scholar
  14. 14.
    Schernthaner G, Grimaldi A, Di Mario U, Drzewoski J, Kempler P, Kvapil M, Novials A, Rottiers R, Rutten GE, Shaw KM. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 2004; 34(8):535–542.CrossRefPubMedGoogle Scholar
  15. 15.
    A desktop guide to Type 2 diabetes mellitus. European Diabetes Policy Group 1999. Diabet Med 1999;16(9):716–730.CrossRefGoogle Scholar
  16. 16.
    Standards of medical care in diabetes. Diabetes Care 2004;27(Suppl 1):S15–S35.Google Scholar
  17. 17.
    Cohen KL, Harris S. Efficacy of glyburide in diabetics poorly controlled on first-generation oral hypoglycemics. Diabetes Care 1987;10(5):555–557.CrossRefPubMedGoogle Scholar
  18. 18.
    Dornhorst A. Insulinotropic meglitinide analogues. Lancet 2001;358(9294):1709–1716.CrossRefPubMedGoogle Scholar
  19. 19.
    Hirschberg Y, Karara AH, Pietri AO, McLeod JF. Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin. Diabetes Care 2000;23(3):349–353.CrossRefPubMedGoogle Scholar
  20. 20.
    Goldberg RB, Einhorn D, Lucas CP, Rendell MS, Damsbo P, Huang WC, Strange P, Brodows RG. A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. Diabetes Care 1998;21(11):1897–1903.CrossRefPubMedGoogle Scholar
  21. 21.
    Rosenstock J, Hassman DR, Madder RD, Brazinsky SA, Farrell J, Khutoryansky N, Hale PM. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care 2004;27(6):1265–1270.CrossRefPubMedGoogle Scholar
  22. 22.
    Zimmerman BR. Sulfonylureas. Endocrinol Metab Clin North Am 1997;26(3):511–522.CrossRefPubMedGoogle Scholar
  23. 23.
    Cheng AY, Fantus IG. Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ 2005; 172(2):213–226.PubMedGoogle Scholar
  24. 24.
    Simonson DC, Kourides IA, Feinglos M, Shamoon H, Fischette CT. Efficacy, safety, and dose–response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group. Diabetes Care 1997;20(4):597–606.CrossRefPubMedGoogle Scholar
  25. 25.
    Rosenstock J, Samols E, Muchmore DB, Schneider J. Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group. Diabetes Care 1996;19(11):1194–1199.CrossRefPubMedGoogle Scholar
  26. 26.
    Groop LC. Sulfonylureas in NIDDM. Diabetes Care 1992;15(6):737–754.CrossRefPubMedGoogle Scholar
  27. 27.
    Groop L, Groop PH, Stenman S, Saloranta C, Totterman KJ, Fyhrquist F, Melander A. Comparison of pharmacokinetics, metabolic effects and mechanisms of action of glyburide and glipizide during long-term treatment. Diabetes Care 1987;10(6):71–78.CrossRefPubMedGoogle Scholar
  28. 28.
    Moses RG, Gomis R, Frandsen KB, Schlienger JL, Dedov I. Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes. Diabetes Care 2001;24(1):11–15.CrossRefPubMedGoogle Scholar
  29. 29.
    Hollander PA, Schwartz SL, Gatlin MR, Haas SJ, Zheng H, Foley JE, Dunning BE. Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care 2001;24(6):983–988.CrossRefPubMedGoogle Scholar
  30. 30.
    Stenman S, Melander A, Groop PH, Groop LC. What is the benefit of increasing the sulfonylurea dose? Ann Intern Med 1993;118(3):169–172.PubMedGoogle Scholar
  31. 31.
    Blaum CS, Velez L, Hiss RG, Halter JB. Characteristics related to poor glycemic control in NIDDM patients in community practice. Diabetes Care 1997;20(1):7–11.CrossRefPubMedGoogle Scholar
  32. 32.
    Leslie RD, Williams R, Pozzilli P. Clinical review: Type 1 diabetes and latent autoimmune diabetes in adults: one end of the rainbow. J Clin Endocrinol Metab 2006;91(5):1654–1659.CrossRefPubMedGoogle Scholar
  33. 33.
    Fardoun RZ. Carvedilol versus cardioselective beta-blockers for the treatment of hypertension in patients with type 2 diabetes mellitus. Pharmacotherapy 2006;26(10):1491–1500.CrossRefPubMedGoogle Scholar
  34. 34.
    Taylor EN, Hu FB, Curhan GC. Antihypertensive medications and the risk of incident type 2 diabetes. Diabetes Care 2006;29(5):1065–1070.CrossRefPubMedGoogle Scholar
  35. 35.
    Efanova IB, Zaitsev SV, Zhivotovsky B, Kohler M, Efendic S, Orrenius S, Berggren PO. Glucose and tolbutamide induce apoptosis in pancreatic beta-cells. A process dependent on intracellular Ca2+ concentration. J Biol Chem 1998;273(50): 33501–33507.CrossRefPubMedGoogle Scholar
  36. 36.
    Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 2005;90(1):501–506.CrossRefPubMedGoogle Scholar
  37. 37.
    Sako Y, Grill VE. A 48-hour lipid infusion in the rat time-dependently inhibits glucose-induced insulin secretion and B cell oxidation through a process likely coupled to fatty acid oxidation. Endocrinology 1990;127(4):1580–1589.CrossRefPubMedGoogle Scholar
  38. 38.
    Zhou YP, Grill VE. Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle. J Clin Invest 1994;93(2): 870–876.CrossRefPubMedGoogle Scholar
  39. 39.
    Poitout V, Robertson RP. Minireview: Secondary beta-cell failure in type 2 diabetes–a convergence of glucotoxicity and lipotoxicity. Endocrinology 2002;143(2):339–342.CrossRefPubMedGoogle Scholar
  40. 40.
    Del Guerra S, Marselli L, Lupi R, Boggi U, Mosca F, Benzi L, Del Prato S, Marchetti P. Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human islets. J Diabetes Complications 2005;19(1):60–64.CrossRefPubMedGoogle Scholar
  41. 41.
    McGavin JK, Perry CM, Goa KL. Gliclazide modified release. Drugs 2002;62(9):1357–1364; discussion 65–66.CrossRefPubMedGoogle Scholar
  42. 42.
    Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355(23):2427–2443.CrossRefPubMedGoogle Scholar
  43. 43.
    DCCT. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329(14):977–986.CrossRefGoogle Scholar
  44. 44.
    Draeger KE, Wernicke-Panten K, Lomp HJ, Schuler E, Rosskamp R. Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide. Horm Metab Res 1996;28(9):419–425.CrossRefPubMedGoogle Scholar
  45. 45.
    Hollingdal M, Sturis J, Gall MA, Damsbo P, Pincus S, Veldhuis JD, Porksen N, Schmitz O, Juhl CB. Repaglinide treatment amplifies first-phase insulin secretion and high-frequency pulsatile insulin release in Type 2 diabetes. Diabet Med 2005;22(10):1408–1413.CrossRefPubMedGoogle Scholar
  46. 46.
    UKPDS. UK Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. UK Prospective Diabetes Study Group. Ann Intern Med 1998;128(3):165–175.Google Scholar
  47. 47.
    Luis Bautista J, Bugos C, Dirnberger G, Atherton T. Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin Ther 2003;25(1):194–209.CrossRefPubMedGoogle Scholar
  48. 48.
    Martin S, Kolb H, Beuth J, van Leendert R, Schneider B, Scherbaum WA. Change in patients' body weight after 12 months of treatment with glimepiride or glibenclamide in Type 2 diabetes: a multicentre retrospective cohort study. Diabetologia 2003;46(12):1611–1617.CrossRefPubMedGoogle Scholar
  49. 49.
    Madsbad S, Kilhovd B, Lager I, Mustajoki P, Dejgaard A. Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study. Diabet Med 2001;18(5):395–401.CrossRefPubMedGoogle Scholar
  50. 50.
    Lazdunski M. Ion channel effects of antidiabetic sulfonylureas. Horm Metab Res 1996;28(9):488–495.CrossRefPubMedGoogle Scholar
  51. 51.
    Thisted H, Johnsen SP, Rungby J. Sulfonylureas and the risk of myocardial infarction. Metabolism 2006;55(5 Suppl 1):S16–S19.CrossRefPubMedGoogle Scholar
  52. 52.
    Scognamiglio R, Avogaro A, Vigili de Kreutzenberg S, Negut C, Palisi M, Bagolin E, Tiengo A. Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes. Diabetes 2002;51(3):808–812.CrossRefPubMedGoogle Scholar
  53. 53.
    Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970;19(Suppl):789–830.PubMedGoogle Scholar
  54. 54.
    Garratt KN, Brady PA, Hassinger NL, Grill DE, Terzic A, Holmes DR Jr. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999;33(1):119–124.CrossRefPubMedGoogle Scholar
  55. 55.
    Huizar JF, Gonzalez LA, Alderman J, Smith HS. Sulfonylureas attenuate electrocardiographic ST-segment elevation during an acute myocardial infarction in diabetics. J Am Coll Cardiol 2003;42(6):1017–1021.CrossRefPubMedGoogle Scholar
  56. 56.
    Rytter L, Troelsen S, Beck-Nielsen H. Prevalence and mortality of acute myocardial infarction in patients with diabetes. Diabetes Care 1985;8(3):230–234.CrossRefPubMedGoogle Scholar
  57. 57.
    Gustafsson I, Hildebrandt P, Seibaek M, Melchior T, Torp-Pedersen C, Kober L, Kaiser-Nielsen P. Long-term prognosis of diabetic patients with myocardial infarction: relation to antidiabetic treatment regimen. The TRACE Study Group. Eur Heart J 2000; 21(23):1937–1943.CrossRefPubMedGoogle Scholar
  58. 58.
    Knowler WC, Sartor G, Melander A, Schersten B. Glucose tolerance and mortality, including a substudy of tolbutamide treatment. Diabetologia 1997;40(6):680–686.CrossRefPubMedGoogle Scholar
  59. 59.
    Sartor G, Schersten B, Carlstrom S, Melander A, Norden A, Persson G. Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation. Diabetes 1980;29(1):41–49.CrossRefPubMedGoogle Scholar
  60. 60.
    Halkin A, Roth A, Jonas M, Behar S. Sulfonylureas are not associated with increased mortality in diabetics treated with thrombolysis for acute myocardial infarction. J Thromb Thrombolysis 2001;12(2): 177–184.CrossRefPubMedGoogle Scholar
  61. 61.
    Stevens RJ, Coleman RL, Adler AI, Stratton IM, Matthews DR, Holman RR. Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. Diabetes Care 2004;27(1):201–207.CrossRefPubMedGoogle Scholar
  62. 62.
    Johnsen SP, Monster TB, Olsen ML, Thisted H, McLaughlin JK, Sorensen HT, Lervang HH, Rungby J. Risk and short-term prognosis of myocardial infarction among users of antidiabetic drugs. Am J Ther 2006;13(2):134–140.CrossRefPubMedGoogle Scholar
  63. 63.
    Lee TM, Chou TF. Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab 2003;88(2):531–537.CrossRefPubMedGoogle Scholar
  64. 64.
    Geisen K, Vegh A, Krause E, Papp JG. Cardiovascular effects of conventional sulfonylureas and glimepiride. Horm Metab Res 1996;28(9):496–507.CrossRefPubMedGoogle Scholar
  65. 65.
    Mocanu MM, Maddock HL, Baxter GF, Lawrence CL, Standen NB, Yellon DM. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation 2001;103(25):3111–3116.PubMedGoogle Scholar
  66. 66.
    Klepzig H, Kober G, Matter C, Luus H, Schneider H, Boedeker KH, Kiowski W, Amann FW, Gruber D, Harris S, Burger W. Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J 1999;20(6):439–446.CrossRefPubMedGoogle Scholar
  67. 67.
    Thisted H, Jacobsen J, Thomsen RW, Johnsen SP, Rungby J. Use of sulphonylureas and mortality after myocardial infarction in diabetic patients: a Danish nationwide population-based study. Diabetologia 2006;57(Suppl 1): Abstract 091.Google Scholar
  68. 68.
    Monami M, Luzzi C, Lamanna C, Chiasserini V, Addante F, Desideri CM, Masotti G, Marchionni N, Mannucci E. Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab Res Rev 2006;22(6):477–482.CrossRefPubMedGoogle Scholar
  69. 69.
    Wascher TC, Boes U. Forearm vascular reactivity is differentially influenced by gliclazide and glibenclamide in chronically treated type 2 diabetic patients. Clin Physiol Funct Imaging 2005; 25(1):40–46.CrossRefPubMedGoogle Scholar
  70. 70.
    Renier G, Mamputu JC, Serri O. Benefits of gliclazide in the atherosclerotic process: decrease in monocyte adhesion to endothelial cells. Metabolism 2003;52(8 Suppl 1):13–18.CrossRefPubMedGoogle Scholar
  71. 71.
    Jennings PE. Vascular benefits of gliclazide beyond glycemic control. Metabolism 2000;49(10 Suppl 2): 17–20.CrossRefPubMedGoogle Scholar
  72. 72.
    O'Brien RC, Luo M, Balazs N, Mercuri J. In vitro and in vivo antioxidant properties of gliclazide. J Diabetes Complications 2000;14(4):201–206.CrossRefPubMedGoogle Scholar
  73. 73.
    Fava D, Cassone-Faldetta M, Laurenti O, De Luca O, Ghiselli A, De Mattia G. Gliclazide improves anti-oxidant status and nitric oxide-mediated vasodilation in Type 2 diabetes. Diabet Med 2002;19(9):752–757.CrossRefPubMedGoogle Scholar
  74. 74.
    Papanas N, Tziakas D, Chalikias G, Floros D, Trypsianis G, Papadopoulou E, Kortsaris A, Symeonidis G, Souliou E, Maltezos E, Hatseras D. Gliclazide treatment lowers serum ICAM-1 levels in poorly controlled type 2 diabetic patients. Diabetes Metab 2006;32(4):344–349.CrossRefPubMedGoogle Scholar
  75. 75.
    Koshiba K, Nomura M, Nakaya Y, Ito S. Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis. J Med Invest 2006;53(1–2): 87–94.CrossRefPubMedGoogle Scholar
  76. 76.
    Derosa G, Franzetti I, Gadaleta G, Ciccarelli L, Fogari R. Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: comparison between glimepiride and metformin. Diabetes Nutr Metab 2004;17(3):143–150.PubMedGoogle Scholar
  77. 77.
    Siluk D, Kaliszan R, Haber P, Petrusewicz J, Brzozowski Z, Sut G. Antiaggregatory activity of hypoglycaemic sulphonylureas. Diabetologia 2002;45(7):1034–1037.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Harald Stingl
    • 1
  • Guntram Schernthaner
    • 2
  1. 1.Department of MedicineRudolfstitung HospitalAustria
  2. 2.Rudolfstiftung Hospital-ViennaAustria

Personalised recommendations